BioNTech IPO
BioNTech is a German biotechnology company developing individualized therapies for cancer and other serious diseases using mRNA technology. The company became globally known for partnering with Pfizer to develop one of the first COVID-19 vaccines approved for emergency use.
Key Facts
| Industry | Biotechnology |
| Founded | 2008 |
| Headquarters | Mainz, Germany |
| Employees | ~5,000 |
| Website | biontech.com |
| Funding | Public since 2019. Market cap varies |
About BioNTech
BioNTech is a German biotechnology company that gained global prominence for co-developing with Pfizer the first widely-approved mRNA COVID-19 vaccine. The company's core focus extends beyond pandemic response to cancer immunotherapy, where it applies its mRNA technology platform to develop personalized cancer vaccines and other oncology treatments that train the immune system to target specific tumor antigens.
Founded by husband-and-wife team Ugur Sahin and Ozlem Tureci, BioNTech has established itself as a leader in mRNA therapeutics with a robust pipeline covering infectious diseases, cancer treatment, and rare diseases. The success of the COVID-19 vaccine provided significant financial resources and validation for the company's mRNA platform technology, enabling accelerated development of its cancer immunotherapy programs. BioNTech's partnerships with pharmaceutical giants like Pfizer, Roche, and Genmab, combined with its proprietary manufacturing capabilities, position it as a key player in the next generation of precision medicine.
IPO Status
BioNTech went public on NASDAQ in October 2019 under the ticker BNTX, raising approximately $150 million in its IPO. The German company also trades on the Frankfurt Stock Exchange. BioNTech's stock price experienced massive growth during the COVID-19 pandemic due to the success of its Pfizer-partnered vaccine. The company continues to trade publicly and has expanded its mRNA platform beyond COVID-19 into cancer immunotherapy and other applications.
Competitors
Frequently Asked Questions
Does BioNTech have a stock?
Yes, BioNTech completed its IPO in October 2019 and trades publicly on NASDAQ under the ticker BNTX. The company also trades on European exchanges.
When is the BioNTech IPO date?
BioNTech already completed its IPO in October 2019. The company is currently publicly traded and does not need another IPO.
How can I buy BioNTech stock?
You can buy BioNTech stock through any brokerage account using the ticker symbol BNTX on NASDAQ. The stock is available to retail investors during regular market hours.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts